Cedar Brook Financial Partners’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-7,426
Closed -$1.02M 192
2024
Q1
$1.02M Buy
7,426
+483
+7% +$66K 0.2% 121
2023
Q4
$950K Buy
6,943
+3,451
+99% +$421K 0.21% 119
2023
Q3
$427K Buy
3,492
+733
+27% +$93.2K 0.11% 189
2023
Q2
$350K Buy
2,759
+58
+2% +$7.53K 0.08% 250
2023
Q1
$349K Buy
2,701
+195
+8% +$25.5K 0.09% 242
2022
Q4
$329K Buy
+2,506
New +$324K 0.09% 250

Other funds holding IBB

Cedar Brook Financial Partners's IBB Position: Q2 2024 in Review

Cedar Brook Financial Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 7,426 shares — an estimated $1.02M sold.

Cedar Brook Financial Partners first reported a position in IBB in Q4 2022 and held it in 6 quarters. The position peaked at $1.02M in Q1 2024. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

  • Cedar Brook Financial Partners reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
  • Cedar Brook Financial Partners sold 7,426 iShares Biotechnology ETF shares in Q2 2024, an estimated $1.02M.
  • Cedar Brook Financial Partners first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 6 quarters.
  • Cedar Brook Financial Partners's iShares Biotechnology ETF position peaked at $1.02M in Q1 2024.
  • 894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2024, filed 15 Jul 2024.